Loading…
Loading…
The MIP notification operates as a price-floor-based non-tariff barrier deployed through India's Foreign Trade Policy (FTP 2023) architecture rather than through the anti-dumping / countervailing-duty route administered by the Directorate General of Trade Remedies (DGTR). This is procedurally significant: DGTR investigations require an industry-injury determination and WTO-compliant notification to the Committee on Anti-Dumping Practices; the DGFT MIP route requires neither, giving the Ministry of Commerce and Industry a faster-deployment and administratively simpler instrument.
The three covered ITC (HS) codes under Chapter 29 are:
Imports presenting a CIF invoice price below the stated threshold are reclassified to "Restricted" — meaning the importer must apply to the Regional Authority (RA) of DGFT for an import authorisation before Customs clearance. In practice this is a price-floor gate: imports at or above the MIP clear under the standard "Free" entry; sub-MIP imports require a discretionary government licence, which in practice functions as an import prohibition for price-competitive Chinese API producers.
China dominates global antibiotic-fermentation upstream supply:
prescriptions worldwide (penicillin-class antibiotics)
economics (economies of scale in dedicated fermentation parks in Inner Mongolia and Hebei), particularly since China relaxed environmental enforcement on older fermentation plants post-2023
The MIP is explicitly the defensive-trade-policy complement to the PLI Bulk Drugs scheme (filed: 2020-07-21-india-pli-bulk-drugs-ksm-di-api). The PLI built domestic capacity (Aurobindo's Atchutapuram fermentation complex, Karnataka Antibiotics' Bengaluru plant expansion, Hetero Labs' 6-APA unit); the MIP protects that newly-built capacity from sub-economic Chinese imports. The sequencing — PLI investment subsidy (2020) → MIP import protection (2026) — mirrors the two-layer model of China's own industrial policy and is structurally peer to:
2025-03-11-eu-critical-medicines-act-proposal)a targeted API-level instrument, not a sectoral tariff or broad import ban.
window reflects the government's desire for a reversible pressure instrument pending PLI capacity maturation.
ensure Indian generic-finished-dose manufacturers exporting to regulated markets (US FDA / EU MHRA) can still source competitively priced Chinese API inputs for export production — protecting India's $28bn pharma-export franchise while shielding the domestic API industry.
DGTR investigation are legally vulnerable under WTO DSB Article XI:1 (prohibits quantitative restrictions); India has previously withdrawn MIP regimes under WTO pressure (e.g., the 2016-era MIP on steel). This constrains how aggressively the MIP can be enforced and how long it will last.
Atchutapuram complex ferments Penicillin G in-house and is directly protected from sub-MIP Chinese competition. The market responded positively on the notification date (+2-3% on NSE).
beneficiary; the MIP floor stabilises KAPL's domestic pricing power for its 6-APA and amoxycillin output.
MIP raises input costs for its formulations business that sources Chinese APIs, partially offset by PLI credit earnings on domestically-sourced inputs.
production from the MIP; domestic-market formulations may see a modest input cost rise if Chinese API pricing had been meaningfully sub-MIP.
low-margin commodity APIs where Chinese producers compete on fermentation scale. The MIP floor is set at levels that eliminate the most aggressively- priced (likely loss-leading) Chinese offers.
the MIP after 30 November 2026, or trigger a formal DGTR anti-dumping investigation (which would confer more durable WTO legitimacy)?
to verify CIF invoice prices for commoditised APIs (round-tripping, transfer pricing within related-party transactions). How rigorously the RA scrutinises sub-MIP applications will determine the de-facto restrictiveness.
antibiotic-fermentation supply chain. Erythromycin, tetracyclines, and cephalosporin intermediates (7-ACA) face similar China-pricing pressure. Whether the MIP is a pilot for a broader Chapter 29 import-policy tightening is the key follow-on risk.